Artrya Secures $0.6M Five-Year Contract to Deploy Salix Platform in U.S.

Artrya’s U.S. Market Breakthrough

Artrya Limited, an Australian medical technology innovator, has taken a significant step in its global expansion by signing a five-year commercial agreement with Tanner Health, a non-profit health system in the U.S. valued at US$0.6 million. This deal represents Artrya’s first commercial revenue in the United States, a milestone that underscores the growing acceptance of its AI-powered Salix Coronary Anatomy platform in clinical practice.

The Salix platform, designed to provide near real-time, point-of-care assessment of coronary artery disease, received FDA 510(k) clearance earlier this year in March 2025. Following this regulatory green light, Tanner Health has integrated the technology across its network of five hospitals, cardiovascular centers, and 30 physician practices, making it available for clinical use on patients undergoing coronary CT angiograms.

Strategic Partnership and Commercial Model

The agreement with Tanner Health is structured as a Software-as-a-Service (SaaS) license with a monthly subscription fee over 60 months. Importantly, it also lays the groundwork for future revenue streams through fee-per-scan payments once additional Salix modules, such as the Coronary Plaque and Coronary Flow modules, obtain FDA clearance. These modules are poised to benefit from U.S. reimbursement under Category 1 CPT codes, enhancing the commercial attractiveness of Artrya’s platform.

John Konstantopoulos, Artrya’s CEO, highlighted the significance of this partnership, noting that Tanner Health’s choice of Salix over competing technologies validates the platform’s clinical utility and user-friendly design. He also emphasized that this collaboration provides a blueprint for further U.S. rollouts, as Artrya seeks to expand its footprint across hospital networks and prepare for upcoming product launches.

Clinical Validation and Integration

The integration of Salix into Tanner Health’s Picture Archiving and Communications System (PACS) and Electronic Medical Record (EMR) systems followed a rigorous validation and enhancement process. This involved close collaboration between Artrya’s integration team and Tanner’s IT and clinical leadership, including Dr. Shazib Khawaja and Dr. Ben Camp, who played key roles in supporting the platform’s clinical adoption.

Loy Howard, Tanner Health’s CEO, expressed confidence in the technology’s ability to aid early detection of heart disease, describing Salix as a vital tool that complements existing diagnostic methods. Tanner Health’s commitment to innovation and patient care is reflected in its decision to be the first U.S. health system to implement this AI-powered solution.

Looking Ahead

Beyond Tanner Health, Artrya is actively pursuing commercial discussions with other U.S. hospital networks, including Northeast Georgia Health System and Cone Health, as well as participants in the SAPPHIRE Study. The company is also preparing for the FDA clearance and launch of its Salix Coronary Plaque module, which promises to broaden its platform capabilities and revenue potential.

While the full financial terms remain confidential, this initial contract and clinical deployment mark a pivotal transition for Artrya from a development-stage company to a revenue-generating enterprise in the competitive U.S. medical technology market.